Neumora’s NMRA-511 Reduces Agitation in Phase Ib Alzheimer’s Study

Neumora Therapeutics has reported positive Phase Ib results for its oral Alzheimer’s disease agitation candidate, NMRA-511, demonstrating clinically meaningful reductions in agitation. In the trial (NCT06546995), 71 patients in the modified analysis set receiving twice-daily NMRA-511 showed placebo-adjusted reductions of 2.6 points at six weeks and 2.1 points at eight weeks on the Cohen-Mansfield Agitation Inventory (CMAI).

Stronger effects were seen in a subgroup of 36 patients with elevated anxiety, where NMRA-511 achieved placebo-adjusted CMAI reductions of 7.6 points at six weeks and 5.6 points at eight weeks. The CMAI measures the frequency of agitated and aggressive behaviours in people with dementia.

NMRA-511, a selective vasopressin 1a receptor antagonist, was well tolerated, with no reports of somnolence or sedation. Based on these data, Neumora plans to advance the drug into a multiple ascending dose study in 2026, followed by a Phase II/III dose-ranging trial.

06-01-2026